This in an aging population is a Addon to Asthma that all should be aware of due to the symptoms being so similar it is hard to diagnose.
Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the obstructive airway diseases and patients experience worse outcomes compared with asthma or COPD alone. Patients with ACOS have the combined risk factors of smoking and atopy, are generally younger than patients with COPD and experience acute exacerbations with higher frequency and greater severity than lone COPD. Pharmacotherapeutic considerations require an integrated approach, first to identify the relevant clinical phenotype(s), then to determine the best available therapy. The authors discuss the array of existing and emerging classes of drugs that could benefit those with ACOS and share their therapeutic approach. A consensus international definition of ACOS is needed to design prospective, randomized clinical trials to evaluate specific drug interventions on important outcomes such as lung function, acute exacerbations, quality of life and mortality.
The full text of the article can be read here https://www.medscape.com/viewarticle/780902
Osaruname Osayi-OsazuwaIt would be interesting to know and compare both outcomes of pharmaceuticals and cannabinoids among certain age groups. Cannabis has had immense...It would be interesting to know and compare both outcomes of pharmaceuticals and cannabinoids among certain age groups. Cannabis has had immense contributions to health outcomes for patients with chronic conditions.Show more2 years ago
You need to be a member of this group before you can participate in this discussion.